Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05679388 · ClinicalTrials.gov registry record · Phase 1
A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
A Phase 1 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT05679388 is a Phase 1 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 60 participants.
The verdict
NCT05679388, a Phase 1 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
Researchers leading this study hope to learn about the safety of combining the study drug relugolix with another study drug called itraconazole or ritonavir in prostate cancer. This study is for individuals who have advanced prostate cancer and plans to have medical castration (the use of medications or chemicals to lower hormone production in the testicles). Your participation in this research will last up to 1 month. The purpose of this research is to gather information on the safety and effectiveness of relugolix in combination with ritonavir or itraconazole. The goal of this research is to find out if combining two medications (relugolix and itraconazole or relugolix and ritonavir) could possibly lead to using less relugolix, which is an expensive drug.
Interventions
- DRUG Itraconazole
- DRUG Ritonavir
- DRUG Relugolix Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-02-13 |
| Est. Completion | 2024-08-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05679388
The ClinicalTrials.gov registry entry for NCT05679388 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Itraconazole is the first listed.
NCT05679388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05679388 about?
NCT05679388 is a clinical study titled "A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients". Researchers leading this study hope to learn about the safety of combining the study drug relugolix with another study drug called itraconazole or ritonavir in prostate cancer. This study is for individuals who have advanced prostate cancer and plans to have medical castration (the use of medication...
What is the current status of trial NCT05679388?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-02-13. Estimated completion is 2024-08-05.
What interventions are being tested in trial NCT05679388?
The interventions under investigation include: Itraconazole (DRUG), Ritonavir (DRUG), Relugolix Pill (DRUG).
Who is sponsoring clinical trial NCT05679388?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.